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Abstract
Hepatocellular carcinoma (HCC) develops in the con-
text of environmental risk factors like chronic viral hep-
atitis, diabetes and alcohol exposure, often associated 
to an increased risk of cirrhosis. Antiviral treatments 
that are effective to counteract hepatitis B and C may 
also attenuate the risk of tumor development. Howev-
er, since hepatitis B-related carcinogenesis is promoted 
independently of the onset of cirrhosis, such antiviral 
treatments as nucleo(t)side analogs can promote re-
gression of cirrhosis, prevent clinical decompensation 
and variceal bleeding but not HCC. This means that 
in successfully treated patients with cirrhosis, HCC is 
often the consequence of their extended survival. In 
hepatitis C patients, a sustained virological response 
to interferon-based therapies can reduce the rate of 
HCC development, even in patients with cirrhosis who 
experience histological regression of their liver disease. 
Future therapies aimed at this endpoint in at risk pop-
ulations should take into consideration pretreatment 
patient stratification for host, viral and environmental 
risk factors. In this context the recent discovery of sin-
gle nucleotide polymorphisms involved in the immune 
system function and tumorigenesis, might permit en-
rollment of populations of patients enriched with HCC 
risk factors for targeted chemopreventive therapies. 
This could finally pave the way to personalized algo-
rithms, as already seen in the diagnosis and treatment 
schemes for chemoprevention.
© 2013 Baishideng. All rights reserved.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in men and seventh in women, accounting 
for 7% of  all cancers, and the third most common cause 
of  cancer related death, worldwide[1]. HCC is character-
ized by peculiar biological and clinical features that may 
be relevant to primary and secondary prevention strate-
gies. Indeed, up to 95% of  all HCCs occur in the context 
of  known and preventable risk factors, such as chronic 
viral hepatitis, alcohol abuse and cirrhosis (Table 1). Sec-
ondly HCC is one of  the few cancers that can be diag-
nosed by radiological techniques, hence avoiding invasive 
diagnostic methods. Lastly, HCC is the only cancer that 
does not contraindicate patients to organ transplantation 
but actually benefits from liver transplantation in accu-
rately selected patients. These rather unique features of  
HCC, in theory, could be used to implement therapeutic 
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and diagnostic measures to reduce or prevent the rate 
of  HCC development in patients at risk, enforce surveil-
lance programs in at risk patients aimed at early diagnosis 
and individualize treatment options based upon patient 
and tumor characteristics once the tumor has developed. 
Some of  these points have been thoroughly investigated 
by clinical research studies and have led to significant 
advances in clinical practice that include the development 
of  specific guidelines on surveillance protocols and on 
individualized treatment algorithms for HCC. Less suc-
cessful have been attempts to design primary prophylaxis 
studies in at risk populations, such as those with hepatitis 
B virus (HBV) or hepatitis C virus (HCV), a fact that is 
especially worrisome as HCC arising in these patients still 
represents the core of  the HCC epidemic in most coun-
tries. Indeed, chronic HBV and HCV infection affect 
roughly 400 and 200 million people, respectively, world-
wide, and are the current leading causes of  liver-related 
death and the main indication for liver transplantation in 
developed countries[2]. 
HCC RISK FACTORS
Hepatic disease status
HCC almost invariably occurs in a histologically abnor-
mal liver, the mere existence of  chronic liver disease 
representing a potential risk for the development of  this 
tumor. Indeed, on the top of  specific virus mechanisms 
that may be directly carcinogenetic to the liver, chronic 
necro-inflammation and accumulation of  reactive oxygen 
species contribute to carcinogenesis through chromo-
somal injury[3]. Cirrhosis, the end stage consequence of  
hepatic inflammation resulting in nodular transforma-
tion of  the liver, is considered a premalignant condition, 
independently of  etiology. Whether the association of  
cirrhosis with HCC reflects a long lasting exposure to 
carcinogenetic agents capable of  causing liver cell inflam-
mation or a carcinogenetic effect of  disrupted lobular 
organization, is a matter of  debate[4]. 
The prevalence of  cirrhosis in persons with HCC is 
about 80%-90% in autopsied series worldwide, whereas 
approximately only 10%-20% of  HCCs may be encoun-
tered in non-cirrhotic patients[5]. However, only a few 
non-cirrhotic patients with HCC have absolutely normal 
liver histology, as the majority show fibrosis stages that 
range from no fibrosis (F0) to septal (F2) and bridging 
fibrosis (F3) with necroinflammation, steatosis, and liver 
cell dysplasia[6-8]. 
In a detailed study from Japan involving 490 untreat-
ed patients with chronic hepatitis C, the HCC incidence 
per 100 person years increased with the stage of  fibrosis 
at diagnosis, from 0.4 among patients with stage F0 or 
F1 to 1.5, 5.1 and 6.9 among those with fibrosis stages 
F2, F3 and F4, respectively[9]. The presence of  large cell 
change[10], irregular regeneration of  hepatocytes and mac-
roregenerative nodules have been evaluated as morpho-
logic predictors of  HCC in cirrhosis independently of  
baseline disease[10-14]. 
Cirrhosis is not only driven by viral hepatitis but can 
also be the consequence of  other conditions like he-
mochromatosis, Wilson’s disease, antitrypsin deficiency, 
primary biliary cirrhosis, and autoimmune hepatitis[3]. 
Patients with cirrhosis stemming from genetic hemochro-
matosis have a 20-fold relative risk of  developing HCC, 
compared to the general population, with an annual in-
cidence of  about 3%-4%[15]. In general, the risk of  HCC 
in patients with cirrhosis increases in parallel to ageing, 
male gender, disease activity, degree of  liver cell prolifera-
tion, presence of  hepatobiliary phenotype on liver cells 
and serum level of  alfa-fetoprotein. Patients with more 
advanced Child-Pugh scores are at higher risk of  liver 
cancer, Child-Pugh class B/C patients having a 3-fold in-
creased risk compared to Child Pugh A patients[16,17]. 
Viral factors
HBV: The annual incidence of  HCC in patients with 
chronic hepatitis B, ranges from 2% to 5%, in strict cor-
relation with the histological stage of  the underlying liver 
disease, serologic status and geographic area[18]. Chronic 
HBV infection is commonly considered a primary risk 
factor for the development of  HCC, exerting its pro-
oncogenic properties through both indirect and direct 
mechanisms[19-23]. The indirect mechanisms are related to 
its propensity to induce continuous or recurrent phases 
of  liver necroinflammation and to promote the progres-
sion of  chronic hepatitis to cirrhosis, often preceding 
the development of  HCC[24]. Most cases of  HBV-related 
HCC (70%-90%) occur in patients with cirrhosis second-
ary to chronic necroinflammation, but HBV itself  can 
cause HCC in the absence of  cirrhosis through direct 
carcinogenic mechanisms that have been related to the 
capacity of  HBV to integrate into the host’s genome and 
to produce proteins (X protein and truncated preS-S pro-
tein) with potential transforming properties[25]. 
In Europe, HBV-related HCC is associated with cir-
rhosis in the majority of  patients[26,27], whereas this is not 
true in Asia and Africa where the tumor is common also 
among carriers with mild hepatic fibrosis, likely as a con-
sequence of  long standing infection that is often acquired 
perinatally[28-30]. 
HCC risk may be modulated by viral load[31-35], even 
when this predictor is measured years before tumor di-
agnosis, and can be modified also by serum hepatitis B e 
antigen (HBeAg) persistence and hepatitis B surface anti-
gen (HBsAg) status[31,36-38]. 
Recently, it has been demonstrated that HCC may 
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  HBV Metabolic syndrome Male sex 
  HCV Genetics 
Table 1  Risk factors for hepatocellular carcinoma
HIV: Human immunodeficiency virus; HBV: Hepatitis B virus; HCV: 
Hepatitis C virus.
also develop in Asian carriers with inactive hepatitis (i.e., 
persistently normal alanine transaminase and serum HBV 
DNA < 2000 IU/mL)[26,27,31,39] and HCC was also found 
to develop in a significant number of  patients from 1 
year to more than 10 years following spontaneous clear-
ance of  serum HBsAg, with a higher risk among patients 
who had HBsAg seroclearance after 50 years of  age[40]. 
Other studies with sensitive amplification assays have 
shown that HBV DNA persists in serum or liver as an 
occult HBV infection, even following spontaneous se-
rologic recovery from transient HBV infection (HBsAg-
negative status)[41]. 
The estimated incidence rates of  HCC in subjects 
with chronic HBV infection in East Asian countries is 
0.2 per 100 person-years in inactive carriers, 0.6 per 100 
person-years for those with chronic HBV infection with-
out cirrhosis, and 3.7 per 100 person-years for those with 
compensated cirrhosis; while in Europe/North America 
the HCC incidence rate was 0.02 per 100 person-years in 
inactive carriers, 0.3 per 100 person-years in subjects with 
chronic HBV without cirrhosis, and 2.2 per 100 person-
years in subjects with compensated cirrhosis[42]. 
Male sex, positive family history and African origins 
are added risk factors for HCC development in HBV 
positive patients[28-30]. Genotype B of  the HBV seems 
to be associated with lower rates of  HCC development 
compared to genotype C of  HBV[43-48], since it is char-
acterized by anticipated HBeAg seroconversion, higher 
rates of  sustained remission after HBeAg seroconversion, 
less active hepatic necroinflammation and slower progres-
sion to cirrhosis. Genotype A infections have a generally 
more favorable outcome than genotype D infections 
which predominate in the Mediterranean basin[49,50]. 
HCV: Chronic infection with HCV affects more than 
170 million individuals, representing a major cause of  
morbidity and anticipated liver-related death in western 
countries and Japan. HCC is the dominant, first to appear 
complication of  patients with long standing infection 
complicated by cirrhosis, which in fact is considered the 
main risk factor for HCC in patients with HCV infection, 
as only a minority of  HCC cases develop in patients with 
mild-to-moderate HCV disease. Malignant transforma-
tion of  hepatocytes occurs through a pathway of  in-
creased liver cell turnover, induced by chronic liver injury 
and regeneration in a context of  inflammation and oxida-
tive DNA damage[51] which facilitates the occurrence of  
genetic and epigenetic alterations that over decades can 
lead to the development of  HCC. Still there are lines of  
evidence that support a direct role for HCV in cancer 
promotion[52]. Clinically this is supported by the incidence 
of  HCC in HCV-related cirrhosis being higher than that 
reported in cirrhosis resulting from other liver diseases 
such as autoimmune hepatitis or metabolic syndrome[53]. 
Whether HCV genotype 1b produces a higher risk of  
HCC development compared to other HCV genotypes, is 
debatable, yet de facto reinforces the concept that HCV 
itself  may promote HCC[54]. 
The HCV genome consists of  a single stranded posi-
tive sense RNA of  approximately 9.6 kb in length, that 
encodes a 327 kDa polyprotein that is processed into 
10 mature structural and non structural viral proteins[55]. 
HCV proteins have been shown to impact on cell signal-
ling, transcriptional modulation, transformation, apopto-
sis, membrane rearrangements, vesicular trafficking and 
translational regulation[52]. Four of  the HCV gene prod-
ucts (core, NS3, NS4B and NS5A) show transformation 
potential in cell culture systems. Transgenic mouse mod-
els support HCV induced carcinogenesis, with transgenic 
lineages with high level liver specific expression of  the 
core protein and transgenic mice for the two envelop 
proteins E1 and E2 developing HCC even in the absence 
of  hepatic inflammation[56,57]. HCV can also induce endo-
plasmic reticulum (ER) stress, a homeostatic mechanism 
that regulates cellular metabolism and protein synthesis 
in response to perturbations in protein folding and bio-
synthesis[58]. Persistent ER stress may result in intra- and 
extra-cellular accumulation of  DNA-damaging factors 
known to predispose cells to mutagenesis.
Human immunodeficiency virus: Human immuno-
deficiency virus (HIV) infection significantly increases 
the risk of  liver-related morbidity and mortality, primar-
ily because during the highly active antiretroviral therapy 
(HAART) era an important reduction in HIV-related 
complications has occurred, leading to the emergence of  
co-infection with HBV (6%-14%) and HCV (25%-30%) 
as hepatotoxic factors in addition to excessive alcohol 
consumption, non-alcoholic fatty liver disease and drug-
induced liver injury[59]. 
While the MORTAVIC study in 2001 indicated HCC 
to be responsible for 25% of  all liver deaths in HIV pa-
tients, in the HAART era there are studies showing HCC 
developing in co-infected patients to be more aggres-
sive, to present at an earlier age and to less frequently be 
curable compared to HCC developing in HCV mono-
infected patients. A direct oncogenic effect of  the virus 
has therefore been hypothesized by some[60,61]. 
Environmental risk factors
Alcohol: Chronic consumption of  more than 80 g of  
ethanol per day for more than 10 years increases the risk 
of  HCC by approximately 5-fold; in women even smaller 
quantities of  alcohol consumption (10 g/d) are associated 
with a significant (24%) increase of  HCC risk[62]. Alcohol 
abuse in patients with chronic hepatitis C doubles the risk 
for HCC, due to a synergism between alcohol and hepa-
titis C in anticipating HCC onset or causing more severe 
histological tumor patterns. In a HCC cohort in Austria, 
alcoholic liver disease was the likely cause of  HCC in 
35% of  subjects[63], whereas in the United States, the 
hospitalization rate for HCC related to alcoholic cirrho-
sis is (8-9)/100 000 people per year compared to about 
7/100 000 people per year for hepatitis C[64]. Heavy alco-
hol consumption can lead to liver damage by direct liver 
cell injury and generation of  toxic metabolites, thereby 
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hepatic disease[76-79]. 
In patients with cirrhosis, there is a striking gender 
imbalance in HCC incidence, with a predominance for 
males independently from geographic area, etiologic fac-
tors and ethnicity with a male to female ratio between 
2:1 to > 4:1 being reported across studies[80]. While male 
preponderance could just reflect the greater incidence 
of  viral hepatitis and alcohol-related disease in males, it 
could also be related to hormonal diversity. High serum 
levels of  testosterone have been associated with increased 
HCC risk in nested case-control studies of  HBV carriers 
in Taiwan and Shanghai[81], while a cross-sectional study 
in male veterans with chronic HCV in the United States 
associated higher total serum levels of  testosterone with 
risk of  advanced hepatic fibrosis and inflammatory activ-
ity, without examining the association with HCC[82]. 
Among the complex molecular mechanisms behind 
gender disparities in HCC, estrogens may play a role in 
increasing interleukin-6 (IL-6) production and modula-
tion of  gene expression through FOXA transcription 
factors that have been shown to prevent HCC develop-
ment in experimental models. However, more data are 
still needed to define the implication of  sexual hormones 
in the molecular pathogenesis of  HCC[83]. 
Single nucleotide polymorphisms associated with HCC
Genetic host factors play an important role in HCC de-
velopment. The most common form of  genetic variation 
between individuals is single nucleotide polymorphisms 
(SNPs) which are a variation in a DNA base at a par-
ticular nucleotide locus. A common SNP is defined by 
having a minor allele frequency of  at least 5%. In stud-
ies designed with a “candidate gene approach”, a limited 
number of  biologically plausible SNPs were tested. The 
starting hypothesis is that a given variant in a specific 
gene involved in a pathway that influences HCC devel-
opment can sufficiently alter either protein function or 
expression, and result in the modulation of  cancer risk. 
Another approach to study genetic factors is through 
“genome wide association studies” (GWAS). These stud-
ies are by definition “hypothesis free”, and compare al-
lele/genotype frequency of  common variants between 
cases and unaffected controls and test 100 000 of  tag 
SNPs reflecting common genetic variations across the 
entire human genome. To reach GWAS significance (P 
value = 0.05/number of  SNPs tested) a P value in the 
order of  < 10-8 is typically required[84]. 
To identify susceptible genetic variants for HCV- and 
HBV-related HCC many genetic association studies have 
been conducted; unfortunately most publications suffer 
from major methodological drawbacks because of  their 
case-control, retrospective and single center design, main-
ly involving selected Asian populations. This minimizes 
the potential importance of  ethnic diversity, calling for 
external validation in populations of  different ancestry 
before effectively translating results to clinical practice. 
Prospective cohort studies conducted in large homo-
geneous populations with sufficient number of  events 
transforming the liver in a mitogenic and mutagenic en-
vironment. This not only causes development of  liver 
fibrosis and cirrhosis[65,66], but also increases conversion 
of  pro-carcinogens to carcinogens through oxidation and 
metabolism of  ethanol in the liver[67]. Acetaldehyde and 
oxygen free radicals deriving from ethanol metabolism 
may also directly induce cell damage by initiating peroxi-
dation of  membrane lipids, through oxidative stress[68]. 
Metabolic syndrome: Diabetes is an independent risk 
factor for HCC; a recent surveillance epidemiology and 
end results based re-analysis has shown a 2-3-fold in-
crease in the risk of  HCC, regardless of  the presence of  
other major risk factors[69]. Further evidence that obesity 
and diabetes are either jointly or independently associated 
with an increased risk of  HCC is provided by an Italian 
case control study and by several large-scale epidemiolog-
ical studies, that have associated the overweight and obe-
sity pandemic in the general population with an increase 
in HCC risk[70].
In a cohort of  900 000 American adults, the risk of  
dying from liver cancer was 4.5 times higher in men with 
a body mass index of  35 kg/m2 or above compared to 
men with a normal body mass index (18.5-24.9 kg/m2)[71]. 
A meta-analysis of  case control and cohort studies con-
cluded that the relative risk of  liver cancer was 1.17 for 
overweight subjects and 1.89 for obese patients[72]. These 
and other studies contribute to the increased recognition 
of  non-alcoholic steatohepatitis (NASH) as a cause of  
cirrhosis and HCC, with many patients progressing to 
liver cancer without histological evidence of  advanced 
fibrosis or cirrhosis[73,74].
A yearly cumulative incidence of  HCC in 2.6% of  
patients with NASH compared to 4.0% of  those with 
HCV over a median follow-up time of  3.2 years was also 
demonstrated in patients referred for liver transplant 
evaluation at Cleveland Clinic in Ohio[75]. Interestingly, in 
this cohort of  patients, older age at diagnosis of  cirrhosis 
and any alcohol consumption were independently associ-
ated with the development of  HCC in a NASH-cirrhosis 
population, suggesting that alcohol intake, even in socially 
accepted amounts, may potentially increase the risk of  
HCC development both in NASH- and HCV-cirrhotic 
patients.
The precise mechanisms through which metabolic 
factors drive HCC development are complex and beyond 
the scope of  this article; however, major systemic and liv-
er specific molecular mechanisms like insulin resistance, 
hyperinsulinemia, increased expression of  tumor necrosis 
factor signaling pathways and direct lipotoxicity are major 
players in the development of  HCC.
Host-related risk factors
Age and sex: Among host factors, older age and male 
sex have consistently been found in longitudinal studies 
to be associated with an increased risk of  HCC among 
persons with cirrhosis of  different etiologies, with the 
caveat, however, that age might reflect longer duration of  
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during follow-up require a long time to be conducted and 
therefore are still scarce.
The genetic regions found to have a significant sta-
tistical association with HCC at a GWAS level in chronic 
hepatitis C patients are the 5’ flanking region of  MICA 
(the MHC class Ⅰ polypeptide-related sequence A gene, 
on chromosome 6p21.33) which is essential for direct im-
mune system functions[85] and isoform1 of  the DEPDC5 
locus on chromosome, where deletion of  the region 
containing DEPDC has been reported in malignant brain 
glioblastomas[86]. Also the MHC class Ⅱ locus presenting 
antigen to CD4 þ (helper) T cells contains three variants 
strongly associated with HCC, probably related to altered 
MHC class Ⅱ proteins that result in an ineffective T-cell 
response[87]. KIF1B was identified as a new susceptibility 
locus for HCC in chronic HBV carriers; the loss of  het-
erozygosity on this locus is a common genetic lesion in a 
broad range of  human cancers[88]. Variations at chromo-
some 8p12 may also promote HCC in patients with HBV 
and risk-associated 8p12 SNPs or haplotypes might have 
an interacting effect on the DLC1 locus (Deleted in Liver 
Cancer 1), which becomes more susceptible to deletion 
or chromosomal loss[89] (Table 2). 
In the HALT-C study cohort a significant associa-
tion between a polymorphism on epidermal growth fac-
tor gene and HCC was detected in a retrospective case-
control study, by the use of  a candidate gene approach[90]. 
With this same approach in HBV patients many other 
genes involved in immune and tumorigenesis processes 
were found to be significantly associated with HCC de-
velopment, among these cytotoxic T-lymphocyte antigen 
4 gene[91], the promoter region of  MCM7 gene and the 
enhancer Ⅱ (EnhⅡ)[92], basal core promoter, and precore 
regions of  HBV[93]. 
Still the SNPs identified so far only partly explain the 
overall variability in HCC susceptibility as they carry a 
rather low risk ratio for HCC development, have been 
mostly assessed in well selected patients where HCC 
tissue was obtained following surgical resection and 
therefore at this moment do not permit prediction at the 
individual and population level. Whole genome sequenc-
ing analysis of  HCCs nodules are promising approaches; 
recently Fujimoto et al[94] have identified etiological di-
verse specific mutation patterns and several mutation of  
chromatin regulators in 27 HCCs.
In 2008 the International Cancer Genome Consor-
tium was launched with the purpose to coordinate large-
scale cancer genome studies in tumors from 50 cancer 
types and/or subtypes that are of  main importance 
across the globe, including HCC. Systematic studies of  
more than 25 000 cancer genomes at the genomic, epig-
enomic and transcriptomic levels are needed to reveal the 
repertoire of  oncogenic mutations, uncover traces of  the 
mutagenic influences, define clinically relevant subtypes 
for prognosis and therapeutic management, and enable 
the development of  new cancer therapies. Hopefully in 
the not so distant future, partial or full cancer genomes 
will routinely be sequenced as part of  the clinical evalu-
ation of  cancer patients and as part of  their on-going 
clinical management[95].
CHEMOPREVENTION
Although all host related HCC risk factors are unmodifi-
able and at this moment do not call for any preventive 
measures, environmental and viral factors can either be 
prevented, suppressed or in some cases cured by effective 
treatments[96]. For viral hepatitis B and C and for HIV 
infection the question is whether the effective antiviral 
treatments that have been developed in the last decade to 
treat patients with virus induced liver disease can be con-
sidered chemopreventive approaches for HCC in parallel.
HBV
Prevention of  HCC in patients with a sustained suppres-
sion of  HBV following interferon or NUC therapy is far 
from being convincingly demonstrated, especially since 
this dramatic and life threatening complication in most 
  Study Patients n SNP locus  Strength Comment 
  Kumar et al[85] CHC 1730 MICA OR 1.3 This study considers HCV-negative individuals as the controls, hence it isn’t useful in 
distinguishing HCC high risk population among HCV-related cirrhotic patientsHCV neg 8376
CHC-HCC 2115
  Miki et al[86] CHC 2390 DEPDC5 OR 2.2 Given the relatively small number of cases in the GWAS phase, the statistical power to 
detect an effect caused by this SNP was only 50%, compared to the 80% recommended to 
detect an association of the expected effect size
CHC-HCC   922
  Zhang et al[88] CHB 1790 KIF1b        0.6 Confounding non-genetic HCC risk factors cannot be ruled out in multivariate analysis
CHB-HCC 2317
  Chan et al[89] CHB   825 DLC1        1.3 Factors of selection bias cannot be excluded because 11.6% of the “genotyping cohort” 
had > 60 g alcohol consumption per day, secondly because 16.5% of the controls received 
antiviral treatment before enrolment
CHB-HCC   595
  Clifford et al[123] HCC1   386 MHC Ⅱ p1 × 10-13 The viral infection status of controls was not ascertained with the consequence that there 
might be hypothetical cases with chronic liver disease Cirrhosis2     86
Controls3   787
Table 2  Genetic associations with hepatocellular carcinoma at genome wide association studies level 
189% HBV or HCV viral infection; 276% HBV or HCV viral infection; 3Not known viral status. CHC: Chronic hepatitis C; CHB: Chronic hepatitis B; GWAS: 
Genome-wide association study; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; SNP: Single nucleotide polymorphism.
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patients occurs many decades after viral infection and 
many years after diagnosis of  hepatitis. 
The benefits of  a virological suppression in patients 
with cirrhosis are easier to evaluate as these patients are 
the closest to developing hepatitis-related complica-
tions. Several studies have shown that HBV patients who 
achieve a virological response to lamivudine are protected 
against HCC during the precirrhotic phase of  infection, 
in fact this is the only complication arising in virological 
responders with preexisting cirrhosis[97-101] (Figure 1). In 
a systematic review of  studies of  nucleos(t)ide analog 
treatment of  patients with HBV it was clearly shown that 
HCC was prevented in patients with chronic hepatitis but 
not in those with cirrhosis, and in general in patients that 
could not achieve complete virological suppression[98]. 
This was confirmed by a recent cohort study from 
Greece where long-term cirrhotic patients responding to 
lamivudine remained at risk of  developing liver cancer[99]. 
All these studies enrolled patients treated with lamivu-
dine or rescued with adefovir, i.e., regimens characterized 
by limited potency and low to moderate genetic barrier, 
which are not recommended any more by International 
guidelines for treatment of  patients with chronic hepatitis 
B in general, and especially in patients with compensated 
cirrhosis. This raised the hope that more potent anti-
HBV drugs, like entecavir and tenofovir, might confer 
an advantage in terms of  HCC prevention in responders 
with cirrhosis, however with disappointing results. A mul-
ticenter study in Italy conducted in patients with com-
pensated cirrhosis who achieved persistently undetectable 
serum HBV DNA during 4 years of  entecavir monother-
apy, showed an annual rate of  neoplastic transformation 
of  the liver of  approximately 2.5%, that mimics the HCC 
rates in untreated HBeAg negative patients in Europe[100]. 
The reasons for these negative results may be many fold: 
it should be recalled that development of  HCC in suc-
cessfully treated patients with cirrhosis is often the conse-
quence of  an extended survival provided by nucleot(s)ide 
analogues (NUCs) preventing clinical decompensation, as 
it was the case in the Italian multicenter study. Another 
explanation is that HBV related liver carcinogenesis is 
likely to be promoted by cellular events that are estab-
lished early during chronic infection with HBV, indepen-
dently on the onset of  cirrhosis. This would explain why 
NUCs can determine regression of  cirrhosis, protection 
from clinical decompensation and variceal bleeding but 
not from HCC development[102-104]. 
HCV
With regards to HCV there is conclusive evidence that 
an sustained virological response (SVR) following inter-
feron (IFN) based therapies can reduce the rate of  HCC 
development, independently of  fibrosis stage[9,105-108]. This 
has been repeatedly shown both by studies in Caucasian 
patients as well as in patients from Asia (Figure 2). Inter-
estingly an SVR does not completely negate the risk of  
HCC, as a small group of  patients will still develop HCC 
in the long term follow-up period, although the annual 
rate is extremely low and reduced compared to non re-
sponders or untreated patients. In an Italian study on 920 
patients with compensated cirrhosis who received IFN 
monotherapy and who were followed-up for a median 
period of  96 mo after treatment completion, Bruno et 
al[109] found that SVR patients had significantly lower rates 
of  HCC (0.66 vs 2.10 per 100 person-years) and liver-
related death (0.19 vs 1.44 per 100 person-years, P < 0.001) 
compared to those with treatment failure. Similar find-
ings were also reported by Cardoso et al[110] in a study that 
analyzed 307 patients with bridging fibrosis or cirrhosis 
followed-up for 3.5 years after the end of  treatment. The 
authors found significantly lower incidence rates per 100 
person-years of  liver-related complications, liver-related 
deaths, and HCC in SVR than in non-SVR patients (0.62 
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vs 4.16, 0.61 vs 3.76 and 1.24 vs 5.85, respectively; P < 
0.001 for all comparisons). A study from France analyz-
ing a cohort of  HCV cirrhotics subjected to repeated 
liver biopsies following an SVR, has linked the protective 
effect of  an SVR on HCC development on regression 
of  cirrhosis[111]. Indeed the 44% of  patients who showed 
cirrhosis regression had 0% occurrence of  HCC during 
a 118 mo follow-up period, while in the 22 patients with-
out cirrhosis regression 3 patients developed HCC. 
Unfortunately the clinical significance of  the protec-
tive effect of  an SVR on HCC development in HCV 
patients with cirrhosis is limited as the vast majority of  
HCV cirrhotics fail to achieve a SVR to IFN plus riba-
virin therapy. In fact cirrhosis is one of  the main factors 
associated with treatment failure to any regimen based 
on IFN, hence most of  HCV cirrhotics even if  treated 
remain at high risk of  HCC. In this context it is impor-
tant to understand the role played by other clinical and 
demographic factors in determining treatment outcome 
to PegIFN plus ribavirin and their interplay with the 
presence of  cirrhosis[112,113]. Not all cirrhotics show re-
duced rates of  SVR, since the presence of  a treatment 
favorable HCV genotype, HCV-2 and in part HCV-3, or 
a protective SNP in the IL-28B coding region in HCV-1 
and HCV-4 patients can lead to SVR rates in the 70% 
range[114-116]. IL-28B has been shown by several studies 
to be the strongest baseline predictor of  treatment out-
come; however its clinical utility in terms of  individual-
ized chemoprevention strategies is limited by its relatively 
low negative predictive power that should never lead to 
treatment deferral, especially considering the significant 
advantages obtained by an SVR in patients with advanced 
fibrosis/cirrhosis[117].
Given that IFN also exerts several important indi-
rect effects in the virus-infected liver that might result 
in tumor prevention, including immunostimulation and 
expression of  HLA class 1 MC, and inhibition of  mu-
tagenic factor beta-UGF, three randomized controlled 
studies were designed to assess if  a long term course of  
low dose PegIFN therapy could reduce the rate of  liver 
related complications in patients with advanced fibro-
sis/cirrhosis who did not achieve an SVR to a full course 
of  PegIFN plus ribavirin therapy[116-120]. Although the 
three studies are hardly comparable due to differences in 
the patients characteristics and in the assigned treatment 
regimens, still they unanimously failed to demonstrate 
any positive impact of  PegIFN maintenance therapy on 
HCC incidence rates[121]. A recent extended analysis of  
the original HALT-C study, performed by Lok et al[122] 
and focused on the development of  HCC, has partially 
contradicted these findings as long-term PegIFN main-
tenance therapy was associated with reduced HCC rates 
in patients with pre-treatment cirrhosis. The cumulative 
incidence of  HCC at 3, 5 and 7 years was 2.6%, 5.1% and 
7.8% in the PegIFN group and 4.0%, 11.1% and 24.2% 
in the untreated group (log-rank test, P = 0.009). 
These results are hard to interpret and require caution 
before suggesting PegIFN maintenance therapy as an ef-
fective chemoprevention strategy in HCV cirrhotics; still 
they provide important clues and directions for future 
studies. Indeed, it shows patients enrolled in chemopre-
vention studies need to be stratified for risk factors at 
baseline; in this particular case enrolling patients with 
different disease severity stage might have precluded 
observation of  a protective effect of  low dose PegIFN 
on HCC development. Secondly it suggests that conduct-
ing studies on high risk rather than medium risk patients 
might provide more clinically meaningful data. 
HIV
Although a detailed discussion about the effect of  anti-
viral therapy in HIV positive patients on HCC develop-
ment is beyond the purpose of  this study, convincing 
evidence has been provided that HCC incidence is rising 
amongst the HIV positive population receiving HAART, 
almost exclusively in patients with concomitant HCV or 
HBV infection. The main explanation behind these find-
ings is probably the increased longevity obtained by ef-
fective antiviral treatment in this population of  patients. 
An investigation of  the Swiss HIV cohort assessed that 
latest CD4þ cell count and CD4þ cell count percentage 
were significantly associated with HCC, but no associa-
tion between HAART use and HCC risk was detected[123]. 
Similarly, Sulkowski et al[124] reported that HCC occurred 
in many patients despite the use of  effective HAART for 
a median of  more than 7 years. 
Thus, antiretroviral therapy is unlikely to modify the 
risk of  HCC in HCV-infected patients in whom the risk 
of  cancer is driven by HCV-related cirrhosis and where 
antiretroviral therapy is also known to have some direct 
hepatotoxic effects which are worsened by co-infection 
with HBV or HCV, raising the possibility that HAART 
per se might hasten the progression to cirrhosis and hence 
HCC[125]. However the role of  HAART on HCC devel-
opment is controversial because its ability to preserve 
immune system functions could in theory provide a 
putatively more active anti-tumor response, since once 
HCC has developed, chronically low CD4+ and CD8+ 
lymphocyte counts may result in more rapid growth and 
spread of  disease. 
CONCLUSION
HCC develops in the context of  readily identifiable envi-
ronmental risk factors, first of  all HBV and HCV, a fact 
that in theory should enable for successful primary pro-
phylaxis. There are solid treatment endpoints that allow 
hepatologists to determine the efficacy of  an antiviral 
regimen and its ability to positively modify both the natu-
ral course of  the disease as well as to reduce the risk of  
HCC development.
Unfortunately in patients with chronic HBV and HCV 
infection tumor prevention is an end point quite difficult 
to assess in patients with early, mild hepatitis whereas it 
can only partially be achieved in patients with established 
cirrhosis given they are at higher risk of  liver cancer. 
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In these patients there is increasing need to improve 
diagnosis rate, ensure equal access to antiviral therapies 
and develop well tolerated therapies that will finally allow 
most, if  not all, patients with viral hepatitis to benefit 
from effective antiviral treatment. In fact it is estimated 
that as few as 35% of  patients with chronic HBV and 
only 25% of  HCV patients are aware of  their disease in 
developed countries, with this number obviously shrink-
ing even more in developing countries[126]. Moreover in 
Europe and the United States, even if  patients are diag-
nosed correctly only 1%-16% of  HBV and HCV patients 
are estimated to receive treatment[127-129]. 
This highlights that one of  the key issues for thera-
pies aimed at HCC chemoprevention is to broaden access 
to therapies by containing costs and increasing disease 
awareness, or eventually concentrate treatment in those 
more at risk of  HCC development. Performing prospec-
tive studies where patients are stratified according to 
complex models of  “genomic risk prediction” that incor-
porate various panels of  specific SNPs, is undoubtedly a 
bold and possibly unreachable goal, but still it could lead 
to individualized chemoprevention strategies in the fu-
ture, while reducing the number of  patients needed to be 
enrolled into chemoprevention studies to assess efficacy 
of  a treatment regimen. Until this is reached, second-
ary prevention through surveillance of  risk populations 
aiming at early diagnosis is the only approach to improve 
treatment and survival of  patients with HCC.
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